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Abstract: Dexmedetomidine was introduced two decades ago as a sedative and supplement 
to sedation in the intensive care unit for patients whose trachea was intubated. However, since 
that time dexmedetomidine has been commonly used as a sedative and hypnotic for patients 
undergoing procedures without the need for tracheal intubation. This review focuses on the 
application of dexmedetomidine as a sedative and/or total anesthetic in patients undergoing 
procedures without the need for tracheal intubation. Dexmedetomidine was used for sedation 
in monitored anesthesia care (MAC), airway procedures including fiberoptic bronchoscopy, 
dental procedures, ophthalmological procedures, head and neck procedures, neurosurgery, 
and vascular surgery. Additionally, dexmedetomidine was used for the sedation of pediatric 
patients undergoing different type of procedures such as cardiac catheterization and magnetic 
resonance imaging. Dexmedetomidine loading dose ranged from 0.5 to 5 µg kg-1, and infusion 
dose ranged from 0.2 to 10 µg kg-1 h-1. Dexmedetomidine was administered in conjunction 
with local anesthesia and/or other sedatives. Ketamine was administered with dexmedetomidine 
and opposed its bradycardiac effects. Dexmedetomidine may by useful in patients needing 
sedation without tracheal intubation. The literature suggests potential use of dexmedetomidine 
solely or as an adjunctive agent to other sedation agents. Dexmedetomidine was especially 
useful when spontaneous breathing was essential such as in procedures on the airway, or when 
sudden awakening from sedation was required such as for cooperative clinical examination 
during craniotomies.
Keywords: dexmedetomidine, sedation, nonintubated patients
Introduction
Dexmedetomidine was introduced two decades ago as a sedative and supplement to 
sedation in the intensive care unit for patients whose trachea was intubated.1 However 
dexmedetomidine was quickly adapted by anesthesiologists in the operating room. 
Novel applications have created discussions in many anesthesiology journals, confer-
ences and practices. However, there is still debate between those who approve these 
applications and those who do not.
More recently, dexmedetomidine has been used as a sedative and hypnotic for patients 
undergoing procedures without the need for tracheal intubation. This review will focus 
on the application of dexmedetomidine as a sedative and/or total anesthetic in patients 
undergoing procedures without the need for tracheal intubation. We have reviewed the 
literature on the use of dexmedetomidine, and we would like to emphasize that many 
of these references are case reports that involve only a small number of patients. This 
could be due to the fact that such applications of dexmedetomidine are new and have not Therapeutics and Clinical Risk Management 2010:6 112
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gained popularity, or that approval by the Institutional Review 
Board for a randomized controlled study may be difficult 
because of the innovative applications and the lack of Food and 
Drug Administration (FDA) approval for dexmedetomidine 
use in nonintubated patients. We postulate that a combina-
tion of these reasons has led to the rarity of double-blinded, 
controlled, randomized, prospective studies describing the use 
of dexmedetomidine for patients undergoing procedures that 
do not require tracheal intubation. However, in late 2008, the 
FDA approved the use of dexmedetomidine for nonintubated 
patients requiring sedation prior to and/or during surgical and 
other procedures. We expect that more studies in this field will 
appear in the literature in the near future.
Dexmedetomidine as a sedative
Sedation is commonly needed during procedures which do not 
require general anesthesia with tracheal intubation. Each class 
of sedative drugs has a different combination of anxiolytic, 
hypnotic, amnestic, and analgesic effects. Selection of the 
most appropriate medication for a specific patient requires 
consideration of many factors such as potential drug interac-
tions and pharmacokinetics and pharmacodynamics of each 
drug. The ideal sedative is free of serious adverse effects; is 
not associated with significant drug interactions; does not 
accumulate with repeated dosing even in the presence of 
organ dysfunction; is easy to administer; has a quick and 
predictable onset and dissipation of effect; and is inexpensive. 
Although no sedative is ideal, a number of agents have charac-
teristics which make them useful. Benzodiazepines, opioids, 
and propofol have all been useful in the appropriate setting.2
Dexmedetomidine is a medication that appears to have 
great utility in areas of sedation. Dexmedetomidine, an 
imidazole, is a potent α2-adrenoceptor agonist that has eight 
times greater specificity for α2 receptors than does clonidine.3 
The actions of dexmedetomidine are thought to be mediated 
through post-synaptic α2 receptors which activate pertussis 
toxin-sensitive G proteins; thus, increasing conductance 
through potassium ion channels.4
Dexmedetomidine has previously been used in the inten-
sive care setting in patients that are undergoing mechanical 
ventilation for less than 24 hours; however, more recently 
it has been used for sedation and analgesia in adults and 
pediatric patients undergoing small and minimally invasive 
procedures.
This review focuses on using dexmedetomidine in patients 
undergoing different procedures without tracheal intuba-
tions. References were identified via MEDLINE (through 
to July 2009) with key words including ‘dexmedetomidine’, 
‘sedation’, and ‘nonintubated’. References cited in the 
published articles were also reviewed for possible inclu-
sion. Dexmedetomidine was used for sedation in monitored 
anesthesia care (MAC), airway procedures including fiber-
optic bronchoscopy, dental procedures, ophthalmological 
procedures, head and neck procedures, neurosurgery, and 
vascular surgery. Additionally, the last section of this review 
focuses on using dexmedetomidine for the sedation of pedi-
atric patients undergoing procedures which require sedation. 
We reviewed 15 prospective studies, 9 retrospective studies, 
and 10 case reports/series. Table 1 includes a summary of 
these studies and we suggest using it as a guide when read-
ing each study.
Dexmedetomidine use during 
monitored anesthesia care
The safety and efficacy of dexmedetomidine in nonintubated 
patients requiring sedation for surgical and diagnostic proce-
dures has been evaluated prospectively.5 More patients in the 
placebo group could not be sedated with midazolam alone and 
required additional sedation with propofol or general anesthesia 
to complete the surgical procedure. However, the design of the 
study favored the dexmedetomidine group. It was predicted that 
the group receiving dexmedetomidine would have a superior 
sedation effect when compared to the placebo group because 
patients received an extra sedative. The study would have been 
more convincing if another hypnotic that is commonly used 
during MAC, such as propofol at 50 to 75 µg kg-1 min-1, was 
used instead of saline for comparison. However, the findings 
of the study are important as they demonstrate that the use of 
dexmedetomidine for procedures requiring MAC is safe and 
superior to the combination of midazolam and fentanyl.
In another study, the cardio-respiratory effects of equi-
sedative doses of dexmedetomidine and propofol for intra-
operative sedation were evaluated in forty patients receiving 
nerve blocks for inguinal hernia and hip/knee procedures.6 
Although the number of patients enrolled is small compared 
to the previous study, the study design is more appropriate 
and practical in our opinion. However, it could be that the low 
propofol dose used (38 µg kg-1 h-1) as compared to that used in 
clinical practice for such cases (50 to 75 µg kg-1 min-1) had a role 
in making dexmedetomidine provide a better sedation profile.
Dexmedetomidine use during 
airway procedures
The advantage of dexmedetomidine as a sedative and its 
respiratory profile make many anesthesiologists excited Therapeutics and Clinical Risk Management 2010:6 113
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about using it to anesthetize patients for surgery on the 
airways when maintaining spontaneous ventilation is nec-
essary. Since dexmedetomidine does not negatively affect 
the respiratory rate or depth compared to other sedatives, 
it has proven to be advantageous for such procedures. 
Dexmedetomidine, coupled with local anesthesia, provided 
excellent sedative and operative conditions for awake laryn-
geal framework procedures.7 Dexmedetomidine produced 
virtually minimal undesirable hemodynamic or respiratory 
effects, while allowing for adequate sedation the majority 
of the time.
Ohata and his colleagues8 reported their experience with 
the anesthetic management using high-dose dexmedetomi-
dine for microlaryngeal surgery on a patient maintaining 
spontaneous breathing. Anesthesia was maintained with 
a dexmedetomidine infusion (loading dose of 1.0 µg kg-1 
and infusion rate of 0.5 µg kg-1 h-1; at 30 minutes the infu-
sion rate was increased to 3 µg kg-1 h-1), intermittent small 
doses of fentanyl, and topical application of lidocaine on 
the tongue, pharynx and larynx. Although end tidal CO2 
remained normal, hypotension occurred resulting in the need 
for small doses of ephedrine. The authors emphasized the 
importance of adequate topical anesthesia as essential for 
procedural sedation with dexmedetomidine.
The two previous reports described dexmedetomidine 
administration in different doses. To avoid hemodynamic 
instability, it is recommended that dexmedetomidine be 
administered as a loading dose of 1 µg kg-1 over 10 minutes, 
and then infused in a dose of 0.2–0.7 µg kg-1 h-1. However, 
many clinicians are finding this range inadequate for 
sedation when performing procedures, especially on the 
airways. Ramsay and Luterman9 described the adminis-
tration of dexmedetomidine in doses up to 10 µg kg-1 h-1 
when using it as the sole sedative for procedures on the 
airways. Three patients were hemodynamically stable dur-
ing the procedures and recovery times were not prolonged 
compared to conventional anesthetic. Additionally, one of 
the authors (MS) has reported administering dexmedeto-
midine as a total anesthetic for four infants undergoing 
direct laryngoscopy and bronchoscopy with doses rang-
ing of 2 to 5 µg kg-1.10 In this report, dexmedetomidine 
was administered as boluses of 0.5 µg kg-1 every few 
minutes.
It is important to note that when using dexmedetomidine 
for airway procedures, adding local anesthetic is essential. 
Additionally, many clinicians use what is considered high 
doses of dexmedetomidine, such as up to 10 µg kg-1 h-1 
used in Ramsay’s report,9 in order to complete the procedure. 
Such high doses could affect the hemodynamics in a sedated 
patient without invasive surgeries. However, airway surgeries 
are very stimulating and this could explain the normal heart 
rate and blood pressure in patients undergoing these surgeries 
with high doses of dexmedetomidine.
Dexmedetomidine use during 
fiberoptic bronchoscopy
Dexmedetomidine has been used extensively for flexible 
fiberoptic tracheal intubation alone or in combination with 
other drugs. In a multicenter randomized, double-blind 
study, the safety and efficacy of dexmedetomidine for seda-
tion during elective awake fiberoptic intubation (AFOI) was 
evaluated.11 Following topical anesthesia with lidocaine 
and achieving a Ramsay Sedation Scale score 2, nasal 
or oral intubation using a flexible fiberoptic bronchoscope 
was performed. Fewer dexmedetomidine patients required 
rescue midazolam to achieve and/or maintain targeted seda-
tion (47.3% vs 86.0%, P  0.001). The mean total dose 
of rescue midazolam was lower with dexmedetomidine vs 
placebo (1.07 mg vs 2.85 mg, P  0.001). No patients in 
the dexmedetomidine group required additional medica-
tion other than midazolam to complete the procedure 
while 4 placebo patients required supplemental fentanyl 
or propofol. The incidence of respiratory depression was 
similar in both groups. Not surprisingly, the most common 
adverse events were hypotension (27.3%) with dexmedeto-
midine and hypertension (28.0%) and tachycardia (24.0%) 
with placebo. The hemodynamic stability composite 
endpoint score was similar between dexmedetomidine 
and placebo groups (0.12 vs 0.14). Dexmedetomidine in 
this study did not prove to provide a favorable respiratory 
profile.
In another study, sedation with dexmedetomidine 
(0.7 µg kg-1 h-1) was compared to remifentanil (0.075 µg kg-1 
min-1) by a blinded operator performing AFOI.12 The load-
ing dose of dexmedetomidine in this study (0.4 µg kg-1) is 
lower than the recommended loading dose of (1 µg kg-1) and 
this could explain the more attempts at intubation needed 
in the dexmedetomidine group. In another retrospective 
report, dexmedetomidine was successfully administered 
in conjunction with midazolam and fentanyl to facilitate 
AFOI in twenty patients with cervical spine myelopathy.13 
The advantage of dexmedetomidine in these patients was 
the ability to perform an awake post-intubation neurologi-
cal exam. However the disadvantages included the brady-
cardia and hypotension which developed in 13 patients. 
To counteract the bradycardia and hypotension effects of Therapeutics and Clinical Risk Management 2010:6 118
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dexmedetomidine, Scher and Gitline14 administered low 
dose of ketamine (15 mg kg-1 bolus and then infusion of 
20 mg h-1) in conjunction with dexmedetomidine when 
performing AFOI for a 52-year-old male with history of 
failed direct tracheal intubation. Using dexmedetomidine, 
ketamine, and airway nerve blocks, the patient was com-
fortable, sedated and tolerated the procedure. In another 
report, Bergese and colleagues15 reported on the usefulness 
of dexmedetomidine to facilitate AFOI in four patients one 
of them did not receive topical anesthesia. Dexmeditomidine 
was administered as a bolus of 1 µg kg-1 over 10 minutes 
followed by infusion of 0.5 µg kg-1 h-1. This is the only 
report that used dexmedetomidine for AFOI without using 
local anesthesia.
Dexmedetomidine use during 
dental procedures
Due to its significant properties as sedative and analgesic 
and safe respiratory profile, coupled with its ease of use and 
antisialagogue properties, dexmedetomidine was thought 
to be very useful in dental/oral procedures.16 A random-
ized, double-blind study compared dexmedetomidine and 
midazolam for intravenous sedation during third molar 
surgery under local anesthesia.17 The study proved that dex-
medetomidine sedation was acceptable to patients and com-
parable to midazolam with more predictability, as patients 
receiving dexmedetomidine did not have any restlessness 
or disinhibition. Dexmedetomidine, due to its respiratory 
profile, is safer than midazolam or the combination of mid-
azolam and fentanyl when used by nonanesthesiologists. In 
another interesting study, dexmedetomidine was compared 
to midazolam for sedation in patients with symmetrically 
impacted mandibular third molars.18 In this unique design 
each patient served as a control for him/herself. The study 
revealed that dexmedetomidine may be a better alternative 
to midazolam for intravenous sedation in oral procedures 
not only because of its reliability and safety, but because of 
its analgesic effect providing a satisfactory sedation level 
without any serious side effects. However, dexmedetomidine 
did not provide reliable amnestic effects. In another prospec-
tive study dexmedetomidine was used as the sole sedative 
in fifteen patients undergoing dental procedures.19 Patients 
recommended this sedation 86% of the time although 26% 
of them stated that they remembered initial local anesthetic 
injection.
The literature reveals that dexmedetomidine is now 
recommended as a sedation agent for dental procedure 
especially in patients with high risk for respiratory depression 
and airway obstruction such as obese and a history of sleep 
apnea.
Dexmedetomidine use during 
ophthalmology and other head 
and neck surgeries
The efficacy of dexmedetomidine has been investigated 
during cataract surgery.20 During retrobulbar block, both 
patients and surgeon satisfaction scores (maximum 5) 
were lower in control group [1.9 (0.5)] compared with 
dexmedetomidine group [3.9 (0.6)] (P = 0.016). After the 
dexmedetomidine loading dose, intraocular pressure was 
significantly decreased [12.3 (1.0) mmHg] compared to the 
preoperative value [16.1 (0.8) mmHg] (P  0.05). There 
were no differences in Aldrete Scores or surgeon satisfac-
tion scores between the two groups during the procedure. 
Two patients in dexmedetomidine group needed additional 
doses of 5 µg of dexmedetomidine after the loading dose, 
with one requiring two doses. The results of this study are not 
surprising as the control group did not receive any sedation. 
Although patients’ satisfaction was higher in dexmedetomi-
dine group while compared to saline, the results may differ 
if a continuous infusion of dexmedetomidine following the 
loading dose was used.
In a double-blind study of patients undergoing cataract 
surgery under peribulbar anesthesia, sedation with dexme-
detomidine was compared to that of midazolam.21 Forty-four 
patients randomly received either. The author concluded 
that compared with midazolam, dexmedetomidine did not 
appear to be better for sedation than midazolam in patients 
undergoing cataract surgery due to cardiovascular depression 
and a delay recovery room discharge.
In facial surgeries, dexmedetomidine proved to be an 
excellent agent for sedation especially when the use of oxy-
gen increases the risk of combustion.22 Dexmedetomidine 
was used as one of the primary anesthetic agents for spon-
taneously breathing patients undergoing constructive facial 
surgeries without supplemental oxygen. Dexmedetomidine 
permitted the surgeon to evaluate his surgical correction of 
a right-sided ptosis during bilateral upper blepharoplasty 
immediately prior to beginning a rhytidectomy. The patient 
was able to open and close her eyelid upon request permitting 
the surgeon to assess the adequacy of the corrected ptosis.
In a case report, dexmedetomidine was used in conjunc-
tion with local anesthetic and fentanyl to sedate a patient with 
obstructive sleep apnea, severe obstructive pulmonary disease, Therapeutics and Clinical Risk Management 2010:6 119
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and congestive heart failure undergoing thyroidectomy.23 
A loading dose of 1 µg kg-1 and infusion of 0.2 to 1 µg kg-1 h-1 
were used with supplemental fentanyl. The patient tolerated 
the procedure very well and was able to cooperate with 
simple commands throughout the procedure.
Dexmedetomidine use during 
neurosurgeries
Another advantage of dexmedetomidine is its short action, 
which provides the ability to conduct a wake up test during 
a procedure.22,24,25 Dexmedetomidine in therapeutic doses 
is very effective in surgeries that require awake and com-
municative patients. Dexmedetomidine is especially useful 
during cortical mapping and when communication with the 
patient is necessary.24,25
In a randomized controlled study on craniotomies for 
tumors located near motor cortex, an awake technique using 
dexmedetomidine was compared to a general anesthetic tech-
nique.26 In another study, dexmedetomidine also proved to be 
advantageous as a sedative in neurosurgical procedures done 
in the prone position.27 These studies emphasized the ability 
to quickly awaken the patients when using dexmedetomidine, 
which is a great safety benefit in neurosurgical procedures.
Dexmedetomidine use during 
vascular surgeries
In 56 patients undergoing carotid endarterectomy using 
regional anesthesia, sedation with dexmedetomidine was 
compared to sedation using midazolam and fentanyl.28 
Dexmedetomidine provided an acceptable alternative, with-
out superiority to standard techniques for sedation during 
awake carotid endarterectomy. In another retrospective review 
the incidence of myocardial infarction, stroke, TIA and 
restenosis two years following carotid endarterectomy repair 
were similar between patients underwent general anesthesia 
and patients sedated with dexmedetomidine.29 Addition-
ally, dexmedetomidine in 2 different loading doses (1 and 
0.5 µg kg-1) was efficacious for sedation in patients undergo-
ing vascular procedures such as stent and fistula with local 
anesthesia.30 In the groups receiving dexmedetomidine at 
0.5 µg kg-1 and 1 µg kg-1, 50% and 57% respectively did not 
require any rescue dose of midazolam, while all patients in 
placebo group did. This study shows that dexmedetomidine 
is safe and efficacious for these procedures. However, it does 
not show any superiority of sedation with dexmedetomidine 
over another type of sedatives as dexmedetomidine was com-
pared to placebo. In another case report, dexmedetomidine, 
in conjunction with local anesthesia, provided adequate 
sedation for a patient for axillofemoral bypass graft with 
complicated medical history and difficult to manage airway.31 
Dexmedetomidine was administered as a loading dose of 
1 µg kg-1, then infused at 0.2–0.7 µg kg-1 h-1.
Kaygusus et al32 evaluated the utility of dexmedetomidine 
when compared with propofol during extracorporeal shock-
wave lithotripsy (ESWL) procedures in spontaneously 
breathing patients. The combination of dexmedetomidine 
with small dose of fentanyl was used safely and effectively 
for sedation and analgesia during ESWL. The design of this 
study was excellent in the way that dexmedetomidine was 
compared to propofol and not a placebo. Dexmedetomidine 
sedation was proved to be safe and efficacious compared 
to a normally practiced sedation with propofol.
Dexmedetomidine use 
in procedures performed 
on pediatric patients
Dexmedetomidine has been used off-label as an adjunctive 
agent for sedation and analgesia in pediatric patients in 
the critical care unit and for sedation during noninvasive 
procedures in radiology.33 Although one of the earliest 
applications for dexmedetomidine in pediatric patients 
was to prevent/treat emergence delirium,34 administering 
the drug for sedation during procedure with spontaneously 
ventilating children has increasingly been utilized.35 Today, 
dexmedetomidine is used in pediatric patients for sedation in 
many diagnostic procedures and surgeries including awake 
craniotomies.25
Cardiac catheterization
Although dexmedetomidine has a great respiratory profile, it 
affects blood pressure, heart rate and cardiac output.36 Because 
of this; utilizing dexmedetomidine during cardiac catheterization 
is not advised. Both bradycardia and hypotension may change 
the pressure measurements needed by the cardiologists during 
cardiac catheterization. However, the literature does contain 
few studies regarding using dexmedetomidine in spontaneously 
breathing children undergoing cardiac catheterization.
In a retrospective report which included 20 children 
undergoing cardiac catheterization with spontaneous ventila-
tion, dexmedetomidine was used as the sole anesthetic for the 
procedure.37 Dexmedetomidine sedation was not sufficient by 
itself in 12/20 patients and propofol had to be used. Another 
retrospective analysis of 16 infants and children showed that 
a combination of ketamine and dexmedetomidine provided 
effective sedation for cardiac catheterization in infants and 
children without significant effects on cardiovascular or Therapeutics and Clinical Risk Management 2010:6 120
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ventilatory function.38 The efficacy of sedation was judged 
by the need for supplemental ketamine doses (1 mg kg-1). 
However, in two patients, the dexmedetomidine infusion 
was decreased from 2 to 1 µg kg-1 h-1 at 12 to 15 minutes 
instead of 30 minutes due to bradycardia. As ketamine causes 
tachycardia, its combination with dexmedetomidine seems to 
reverse the bradycardia effects of dexmedetomidine.
The effects of dexmedetomidine-ketamine and propofol-
ketamine combinations on hemodynamics, sedation level, and 
the recovery period in pediatric patients undergoing cardiac 
catheterization was evaluated.39 The dexmedetomidine-
ketamine combination was not superior to a propofol-ketamine 
combination due to insufficient sedation and analgesia and a 
longer recovery time. Again, the literature does not support 
any superiority of dexmedetomidine’s application in cardiac 
catheterization in pediatric patients.
CT and MR imaging
Dexmedetomidine has been used solely to sedate children for 
procedures without stimulation,40 and its use in MRI and CT 
scan are becoming popular. Dexmedetomidine was success-
fully used in 250 patients for sedation for CT imaging.41 This 
study was preceded by a pilot study on 62 patients that showed 
a mean recovery time of 32 ± 18 minutes.42 The same authors 
have utilized a sedation protocol for MRI using dexmedeto-
midine.43 In their review of their sedation protocol, they found 
that utilizing a higher doses of dexmedetomidine was associ-
ated with higher completion of imaging without the need to 
administer other sedative. It is an interesting finding that the 
higher dose of dexmedetomidine (bolus of 3 µg kg-1 and infu-
sion of 2 µg kg-1 h-1) was associated with shorter recovery time 
(24.8 ± 19.5 min). This was due to the lower use of barbiturates 
for rescue due to lower failure of sedation with dexmedetomi-
dine alone. In another study, the sedative, hemodynamic and 
respiratory effects of dexmedetomidine were evaluated and 
compared with those of midazolam in children undergoing 
MRI.44 Patients in dexmedetomidine group had a higher rate of 
imaging completion without the need to add another sedative 
(80% compared with 20% in the midazolam group). The same 
authors compared the sedative, hemodynamic, and respiratory 
effects of dexmedetomidine and propofol in children undergo-
ing MRI.45 In our experience, propofol provides a faster onset 
and offset, more reliable, and predictable anesthetic agent dur-
ing MRI sedation. Dexmedetomidine may be an alternative to 
propofol for nonanesthesiologists or when the patient is at risk 
for desaturation or airway collapse. The literature also reveals 
that in order to increase the success of using dexmedetomidine 
as the sole agent of sedation in MRI, providers must increase 
the doses required for bolus and infusion (2 to 3 µg kg-1 and 
2 µg kg-1 h-1 respectively).
In Summary, the efficacy of dexmedetomidine to provide 
sedation for patients undergoing procedures and surgeries 
varied depending on the clinical situation: efficacy in pediat-
ric patients was greatest during noninvasive procedures, such 
as magnetic resonance imaging, and lowest during invasive 
procedures, such as cardiac catheterization. Efficacy in the 
adult patients was best when local anesthesia was used. 
Dexmedetomidine is relatively unique in its ability to provide 
sedation without causing respiratory depression. It enables 
anesthesiologists to facilitate a rapid patients wake up dur-
ing procedures, especially neurosurgical ones. We conclude 
that dexmedetomidine has no deleterious clinical effects 
on respiration when used in adequate doses and provides 
adequate sedation and effective analgesia. We ascertain that 
dexmedetomidine has the potential for an increasing role 
in anesthesia and sedation. Additionally, dexmedetomidine 
offers an alternative choice to propofol, opioids, and benzo-
diazepines for the sedation of patients whose trachea are not 
intubated during minimally invasive procedures.
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